Company: ZVRA
Filing Date: 2025-03-31
Form Type: DEFA14A
Source: 0001193125-25-068853
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: DEFA14A
Chunk 1
---
 refrain from speculating
on this news. Consistent with our company policy, in the event you are contacted by a member of the media, investment community, or any other party, we ask that you simply respond that you are not authorized to comment on the matter, and immediately
share their name and contact information with Nichol, LaDuane, Rahsaan or Neil.

Similarly, at this time, employees should refrain from personal social
media activity related to the Company, including its investigational or commercial products and any engagements associated with Zevra.

Finally, we ask
that you do not let this become a distraction to you or your teams. We have made tremendous progress over the last two years and we have strong momentum as we deliver on our strategy.

If you have any questions about the news today, please contact your direct supervisor, or Nichol, LaDuane, Rahsaan or Neil, and we will do our best to get you
answers.

Thank you for your commitment to Zevra and the patients we serve.

Sincerely,

NFM

Additional Information and Where to Find It

Zevra Therapeutics, Inc. (the “Company” or “Zevra”) intends to file with the Securities and Exchange Commission (the “SEC”) a
definitive proxy statement on Schedule 14A, containing a form of WHITE proxy card, with respect to its solicitation of proxies for the 2025 Annual Meeting of Stockholders.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) THAT
WILL BE FILED BY ZEVRA, AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED BY ZEVRA WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION.

Investors and security holders may obtain copies of these documents and other documents filed with the SEC by Zevra free of charge through the website
maintained by the SEC at www.sec.gov. Copies of the documents filed by Zevra are also available free of charge by accessing Zevra’s investor relations website at .

Participants in the Solicitation

Zevra, its directors,
executive officers, and employees may be deemed to be participants in the solicitation of proxies with respect to a solicitation by Zevra. Information about Zevra’s executive officers and directors is available under